银河证券海外投行股权项目再添新单！康哲药业登陆新交所实现二次上市

Core Viewpoint - The article highlights the successful secondary listing of Kangzheng Pharmaceutical Holdings Limited on the Singapore Exchange, facilitated by China Galaxy Securities, marking a significant milestone for the company and reflecting the growing trend of Chinese enterprises seeking opportunities in Southeast Asia amid complex international market conditions [2][5][6]. Group 1: Market Context - The international capital market environment has become increasingly complex, with geopolitical and regulatory uncertainties posing significant challenges for some Chinese concept stocks [3]. - Southeast Asia has emerged as a preferred destination for Chinese enterprises to expand overseas, driven by strong economic growth, market potential, and geographical advantages [3]. - The strategic value of capital markets is becoming more pronounced as Chinese companies transition from "product export" to "industrial chain export," leading to increased demand for cross-border financing and M&A services [3]. Group 2: Kangzheng Pharmaceutical's Strategy - Kangzheng Pharmaceutical aims to leverage its secondary listing in Singapore as a strategic pivot to deepen its presence in Southeast Asia [4]. - The company has established differentiated advantages in various therapeutic areas, including cardiovascular, central nervous system, digestive, skin, and ophthalmology since its initial listing in Hong Kong in 2010 [4]. - The listing is viewed as a critical milestone in the company's history, intended to accelerate its internationalization strategy and enhance its global footprint [5]. Group 3: Role of China Galaxy Securities - China Galaxy Securities has played a pivotal role in facilitating the secondary listing of Kangzheng Pharmaceutical, showcasing its capabilities in navigating complex regulatory environments and providing tailored financial services [6][7]. - The firm has a significant local presence in Southeast Asia, with over 2,000 employees and more than 70 researchers, enabling it to understand market nuances and regulatory requirements effectively [7]. - The successful listing of Kangzheng Pharmaceutical follows the previous success of another company, Helen's, indicating a replicable and sustainable model for supporting Chinese enterprises in their international expansion [8]. Group 4: Broader Financial Services - China Galaxy Securities has extended its services beyond IPOs and the Singapore Exchange, successfully assisting various companies in cross-border financing, mergers, and acquisitions [9][10]. - The firm has facilitated significant projects for diverse industries, demonstrating its comprehensive service capabilities in addressing complex financial needs for both Chinese and Southeast Asian enterprises [10]. - As the internationalization of Chinese enterprises accelerates, China Galaxy Securities is positioned to continue playing a crucial role in connecting these companies with global opportunities [11].